Case Report: Complete response with combination oncolytic virus immunotherapy in a patient with stage IV renal cell carcinoma—a promising innovative approach

Case Report: Complete response with combination oncolytic virus immunotherapy in a patient with stage IV renal cell carcinoma—a promising innovative approach

Metastatic renal cell carcinoma stage IV (RCC-IV) remains a therapeutic challenge, with an overall 5-year survival rate of 12%. Conventional chemotherapy and radiotherapy have shown relatively low efficacy in reducing morbidity and mortality, whereas innovative immunotherapies have demonstrated prom...

Full description

Saved in:
Bibliographic Details
Main Authors: Benjamin Gesundheit, Chaim Brauns, Thomas J. Vogl, Alexander Muckenhuber, Christine Weisslein, Harald Schmoll, Ronald Ellis, Yehudit Posen, Jayadeepa Srinivas Raju
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Oncology
Subjects:
renal cell carcinoma
oncolytic virotherapy
intratumoral
immunotherapy
abscopal effect
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1631155/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Metastatic renal cell carcinoma stage IV (RCC-IV) remains a therapeutic challenge, with an overall 5-year survival rate of 12%. Conventional chemotherapy and radiotherapy have shown relatively low efficacy in reducing morbidity and mortality, whereas innovative immunotherapies have demonstrated promising clinical results with fewer adverse events (AEs). Oncolytic virus (OV) immunotherapy has produced remarkable therapeutic effects in many solid tumors, including refractory and end-stage tumors, with intratumoral (IT) injection (IT-OV) suggested to enhance both efficacy and tolerability. We report the clinical course of a patient with RCC-IV who was treated over a period of 3 years with multiple IT injections of various OVs and another immunotherapeutic agent. A complete response—confirmed through periodic radiological surveillance and biopsies—was achieved without any serious side effects, hospital admissions, or surgical interventions throughout the entire treatment course. To our knowledge, this is the first documented case of complete remission of RCC-IV mediated by IT-OV therapy. The rationale and potential of IT-OV therapy as an innovative approach for treating RCC-IV are discussed.
ISSN:2234-943X

Similar Items